Hamm C W, Goldmann B U, Heeschen C, Kreymann G, Berger J, Meinertz T
Department of Cardiology, University Hospital Eppendorf, Hamburg, Germany.
N Engl J Med. 1997 Dec 4;337(23):1648-53. doi: 10.1056/NEJM199712043372302.
Evaluation of patients with acute chest pain in emergency rooms is time-consuming and expensive, and it often results in uncertain diagnoses. We prospectively investigated the usefulness of bedside tests for the detection of cardiac troponin T and troponin I in the evaluation of patients with acute chest pain.
In 773 consecutive patients who had had acute chest pain for less than 12 hours without ST-segment elevation on their electrocardiograms, troponin T and troponin I status (positive or negative) was determined at least twice by sensitive, qualitative bedside tests based on the use of specific monoclonal antibodies. Testing was performed on arrival and four or more hours later so that one sample was taken at least six hours after the onset of pain. The troponin T results were made available to the treating physicians.
Troponin T tests were positive in 123 patients (16 percent), and troponin I tests were positive in 171 patients (22 percent). Among 47 patients with evolving myocardial infarction, troponin T tests were positive in 44 (94 percent) and troponin I tests were positive in all 47. Among 315 patients with unstable angina, troponin T tests were positive in 70 patients (22 percent), and troponin I tests were positive in 114 patients (36 percent). During 30 days of follow-up, there were 20 deaths and 14 nonfatal myocardial infarctions. Troponin T and troponin I proved to be strong, independent predictors of cardiac events. The event rates in patients with negative tests were only 1.1 percent for troponin T and 0.3 percent for troponin I.
Bedside tests for cardiac-specific troponins are highly sensitive for the early detection of myocardial-cell injury in acute coronary syndromes. Negative test results are associated with low risk and allow rapid and safe discharge of patients with an episode of acute chest pain from the emergency room.
在急诊室对急性胸痛患者进行评估既耗时又昂贵,而且常常导致诊断不明确。我们前瞻性地研究了床边检测心肌肌钙蛋白T和肌钙蛋白I在急性胸痛患者评估中的实用性。
连续纳入773例急性胸痛持续时间少于12小时且心电图无ST段抬高的患者,基于特异性单克隆抗体,通过敏感的定性床边检测至少两次测定肌钙蛋白T和肌钙蛋白I状态(阳性或阴性)。在患者到达时及4小时或更久后进行检测,以便在疼痛发作至少6小时后采集一份样本。将肌钙蛋白T检测结果提供给主治医生。
123例患者(16%)的肌钙蛋白T检测呈阳性,171例患者(22%)的肌钙蛋白I检测呈阳性。在47例进展性心肌梗死患者中,44例(94%)的肌钙蛋白T检测呈阳性,47例患者的肌钙蛋白I检测均呈阳性。在315例不稳定型心绞痛患者中,70例(22%)的肌钙蛋白T检测呈阳性,114例(36%)的肌钙蛋白I检测呈阳性。在30天的随访期内,有20例死亡和14例非致命性心肌梗死。肌钙蛋白T和肌钙蛋白I被证明是心脏事件的强大独立预测指标。检测结果为阴性的患者中,肌钙蛋白T的事件发生率仅为1.1%,肌钙蛋白I为0.3%。
针对心脏特异性肌钙蛋白的床边检测对急性冠状动脉综合征中心肌细胞损伤的早期检测高度敏感。检测结果为阴性与低风险相关,可使急性胸痛发作的患者从急诊室快速安全出院。